New Parkinson's drug candidate UCB0022 passes first safety check in small study
NCT ID NCT04867642
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This early-stage study tested a new drug called UCB0022 in 100 people, including healthy volunteers and those with Parkinson's disease. The main goal was to see if the drug is safe and how the body processes it. Researchers gave single and multiple doses to find the right amount and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UP0091 1
London, United Kingdom
Conditions
Explore the condition pages connected to this study.